Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.41 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.41 |
| ▸ | RPA1 | P27694 | 1/20 | 0.37 |
| ▸ | MYC | P01106 | 1/20 | 0.37 |
| ▸ | NR4A1 | P22736 | 1/20 | 0.37 |
| ▸ | PTGER1 | P34995 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | MARS1 | P56192 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18330399 | 0.82 | KDM4E (0.48) | KDM4EGABRA2GABRB2RPA1MYC | |
| SCHEMBL20176153 | 0.80 | GABRA1 (0.34) | PTGER1LMNA | |
| SCHEMBL22062699 | 0.80 | KDM4E (0.43) | KDM4EGABRA2GABRB2RPA1MYC | |
| SCHEMBL24785917 | 0.80 | GABRA2 (0.44) | KDM4EGABRA2GABRB2RPA1MYC | |
| SCHEMBL4425274 | 0.80 | KMO (0.47) | KDM4EGABRA2GABRB2RPA1MARS1 | |
| SCHEMBL17661858 | 0.79 | IDH1 (0.43) | — | |
| SCHEMBL17661884 | 0.76 | NOTUM (0.49) | GABRA2GABRB2LMNA | |
| SCHEMBL19412447 | 0.76 | KCNH2 (0.33) | GABRA2GABRB2 | |
| SCHEMBL19412448 | 0.76 | F11 (0.37) | GABRA2 | |
| SCHEMBL17661859 | 0.75 | P4HTM (0.36) | KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190144393-A1 | FACTOR XIA MACROCYCLES WITH NOVEL P1 GROUPS | BRISTOL MYERS SQUIBB CO (US) | 2019-05-16 | — | — | US | disclosed |
| US-10287288-B2 | Factor XIa macrocyclic inhibitors bearing alkyl or cycloalkyl P2' moieties | BRISTOL-MYERS SQUIBB (US) | 2019-05-14 | — | — | US | disclosed |
| US-20180215755-A1 | FACTOR XIA MACROCYCLIC INHIBITORS BEARING ALKYL OR CYCLOALKYL P2' MOIETIES | BRISTOL MYERS SQUIBB CO (US) | 2018-08-02 | — | — | US | disclosed |
| US-20180215755-A1 | FACTOR XIA MACROCYCLIC INHIBITORS BEARING ALKYL OR CYCLOALKYL P2' MOIETIES | BRISTOL MYERS SQUIBB CO (US) | 2018-08-02 | — | — | US | disclosed |
| US-20180162821-A1 | FACTOR XIA MACROCYCLES WITH NOVEL P1 GROUPS | BRISTOL-MYERS SQUIBB COMPANY | 2018-06-14 | — | — | US | disclosed |
| US-20180162821-A1 | FACTOR XIA MACROCYCLES WITH NOVEL P1 GROUPS | BRISTOL-MYERS SQUIBB COMPANY | 2018-06-14 | — | — | US | disclosed |
| US-20180141932-A1 | DIAMIDE MACROCYCLES AS FACTOR XIA INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2018-05-24 | — | — | US | disclosed |
| US-20180141932-A1 | DIAMIDE MACROCYCLES AS FACTOR XIA INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2018-05-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180141932-A1 | DIAMIDE MACROCYCLES AS FACTOR XIA INHIBITORS | TFPI, TFPI2, F11 | KDM4E 603/4885GABRA2 3975/4885GABRB2 4160/4885 |
| US-20180215755-A1 | FACTOR XIA MACROCYCLIC INHIBITORS BEARING ALKYL OR CYCLOALKYL P2' MOIETIES | TFPI, TFPI2, F11 | KDM4E 1090/4885GABRA2 3437/4885GABRB2 3815/4885 |
| US-20190144393-A1 | FACTOR XIA MACROCYCLES WITH NOVEL P1 GROUPS | F11, F12, TFPI | KDM4E 2077/4885GABRA2 4464/4885GABRB2 4721/4885 |
| US-20180162821-A1 | FACTOR XIA MACROCYCLES WITH NOVEL P1 GROUPS | F11, F12, TFPI | KDM4E 2077/4885GABRA2 4464/4885GABRB2 4721/4885 |
| US-10287288-B2 | Factor XIa macrocyclic inhibitors bearing alkyl or cycloalkyl P2' moieties | TFPI, TFPI2, F11 | KDM4E 1090/4885GABRA2 3437/4885GABRB2 3815/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.